Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported
➤ Phase 2 trial results of gene therapy for diabetic retinopathy
➤ Phase 2 program for tracking glaucoma biomarkers begins
➤ Results from extension study of the first approved treatment for geographic atrophy
➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy
➤ ASCRS news and events
➤ FDA expands eye drop warning list
➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant
➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis
➤ FDA approves additional treatment indication for bispecific antibody
➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy
➤ Company to study personalized medicine for patients with wet AMD
➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy
➤ Pivotal trial for wet AMD therapy begins
➤ Survey evaluates female ophthalmologist experiences
➤ ASCRS news and events
➤ Editorial statement on the nomenclature for refractive lenticule extraction procedure
➤ First patient dosed in Phase 1/2 trial evaluating allogenic cell therapy for corneal edema
➤ IND granted to company investigating therapy for geographic atrophy
➤ Licensing agreement to develop neuroprotective drug
➤ Retinal imaging test detects increased risk for type of dementia
➤ ASCRS news and events
➤ FDA approves presbyopia drop
➤ FDA approves expanded capabilities on anterior segment diagnostic platform
➤ Phase 4 data presented for dry eye disease drug
➤ Extension study for investigational wet AMD treatment demonstrates safety, efficacy
➤ Reports suggest reproxalap NDA might not be approved
➤ Companies partner to develop gene therapy
➤ ASCRS news and events
➤ Positive Phase 3 results in trial investigating topical diabetic macular edema treatment
➤ Positive topline results in Phase 3 trials for retinal vein occlusion treatment
➤ IND filed for drug to treat neuropathic corneal pain
➤ Trial for ‘first-in-class anti-VEGF-complement dual targeting drug’ begins dosing patients
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ Study: large-scale MIGS study
➤ Partnership to advance early disease detection
➤ License agreement to move forward option for cataract surgery sedation
➤ Name change news
➤ ASCRS news and events
➤ FDA approves drop for mydriasis reversal
➤ Inventors of OCT honored with ‘American Nobel Prize’
➤ Preservative-free latanoprost begins U.S. launch
➤ Enrollment complete in myopia treatment trial
➤ ASCRS news and events
➤ First AI foundation model in ophthalmology
➤ 24-month topline data from Phase 3 geographic atrophy therapy
➤ Positive data from Phase 1/2 trial for retinitis pigmentosa, Leber congenital amaurosis treatment
➤ FDA clearance granted for portable retinal imaging system
➤ ASCRS news and events
➤ FDA issues eight warning letters
➤ Positive Phase 2 safety update for investigational treatment of retinal diseases
➤ First-in-human titratable glaucoma therapy system
➤ Companies partner to develop biological dry eye treatment
➤ Geographic atrophy drug development discontinued
➤ ASCRS news and events
➤ Study: 1-year results with IOP-lowering implant
➤ Phase 2 study of investigational dry eye treatment nears enrollment target
➤ Study identifies antibody that could lead to retinitis pigmentosa treatment
➤ Gene therapy for inherited optic neuropathy approved for clinical trials
➤ ASCRS news and events
